10th Annual Microbiome Movement Summit Europe

10th Annual Microbiome Movement Summit Europe is organized by Hanson Wade and will be held from Jan 27 - 29, 2026 at Park Plaza Victoria London, London, England, United Kingdom.

Description:
Drawing on a decade of industry experience, the 10th Microbiome Movement Summit Europe returns to London, as the premiere touchpoint for end-to-end discussions in advancing best-in-class microbiome products beyond traditional gastrointestinal indications.

Over the past 10 years, this community has developed robust and impactful preclinical research, now the focus has shifted to translating this into clinical efficacy and driving towards commercial excellence, in spite of industry headwinds.

Join senior stakeholders from across the microbiome field, including drug developers, academics, consumer health, pharma, investors, service providers and more, to overcome shared challenges, spotlight innovations and collaborate in shaping the future of microbiome therapeutics.

Standing as the field's definitive event uniting stakeholders across biotech, academia, investment and more, the 10th Microbiome Movement Summit Europe remains the only forum driving the translation of microbial research into impactful therapeutics for patients across a variety of indications.

As clinical readouts continue to roll in, next year's meeting looks to dive deeper than the standard readouts, to understand the mechanistic process of these therapeutics, potential implications in broader indications or combination therapies, and how these scientific fundamentals can ultimately support translatability to clinical efficacy and patient benefit.

Speakers: Konstantina Zafeiropoulou, Lab Group Member, Amsterdam University Medical Center, Wouter De Jonge, Professor, Experimental Gastroenterology, Amsterdam University Medical Center, David Paez-Espino, Co-Founder and Chief Technology Officer, Ancilia Biosciences, Dan Brownell, Senior Director, Research and Development, AOBiome, Rikke Nielsen, Founder and Chief Executive Officer, BEO Therapeutics, Yongkyu Kim, Chief Executive Officer, Biomatz, Jos Seegers, Senior Director, Operations, Caelus Health, Jared Kehe, Co-Founder and Chief Scientific Officer, Concerto Biociences, Sou Miyake, Head, Venture Investments, CSB, Isaac Middelmann, EIT Health Accelerator Director, Strategic Fundraising, EIT Health, Benjamin Hadida, Co-Founder and Chief Executive Officer, Exeliom Biosciences, Aran Singanayagam, Research Group Leader, Imperial College London, Gabriela Juárez Martínez, Senior Knowledge Transfer Manager, Microbiome and AMR Lead, Innovate UK, Jelena Cvejic, Visiting Professor, KU Leuven, Claudio Hidalgo, Chief Executive Officer, Microviable Therapeutics, Jason Goldsmith, Senior Director, Medical, Translational and Data Sciences, Nestlé Health Science, Tomas de Wouters, Co-Founder and Chief Executive Officer, PharmaBiome, Ping Hu, R and D Director and Principal Scientist, Procter and Gamble, Livija Deban, Chief Scientific Officer, Prokarium, Denise Kelly, Investment Advisor, Seventure Partners, Tariq Iqbal, Professor, Clinical Microbiome, University of Birmingham, Vittoria Pavoncello, Investment Associate, Zcube, Zambon Research Venture